Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma

With 15 drugs currently approved for the treatment of metastatic renal cell carcinoma (mRCC) and even more combination regimens with immunotherapy on the horizon, there remains a distinct lack of molecular biomarkers for therapeutic efficacy. Our study reports on real-world clinical outcomes of mRCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Viola J., Hernandez-Meza, Gabriela, Agrawal, Prashasti, Zhang, Chiyuan A., Xie, Lijia, Gong, Cynthia L., Hoerner, Christian R., Srinivas, Sandy, Oermann, Eric K., Fan, Alice C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678132/
https://www.ncbi.nlm.nih.gov/pubmed/31319594
http://dx.doi.org/10.3390/cancers11071000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678132/
https://www.ncbi.nlm.nih.gov/pubmed/31319594
http://dx.doi.org/10.3390/cancers11071000

Ejemplares similares